For patients who elect to have prostate cancer screening, the optimal time to discontinue screening is unknown. Our objective was to describe rates and predictors of prostate-specific antigen (PSA) screening among older men in the United States.
INTRODUCTION
The landscape of prostate cancer diagnosis and treatment, particularly in the United States, has been dramatically altered by the identification 1 and widespread use of prostate-specific antigen (PSA) as a screening tool for prostate cancer. 2 Over the last 20 years, the proportion of men presenting with metastases has decreased 75%, and mortality rates have declined more than 30%. 3 Concomitant with these encouraging trends is the estimated 1.3 million men diagnosed with prostate cancer since the introduction of PSA who do not reap a clinical benefit from treatment, because they would not have otherwise known of their cancer during their natural life span. 4 For these reasons, intense controversy exists regarding the appropriate role of PSA-based prostate cancer screening. Recently reported randomized trials have not resolved, but rather have fueled, the ongoing debate. 5, 6 The Prostate, Lung Cancer, and Ovarian Cancer Screening Trial randomly assigned 76,000 men to annual PSA screening or usual care and did not observe a difference in cancer-specific mortality at 10 years, although a significant proportion of men in the control arm underwent PSA screening (approximately 50%). 5 The European Randomized Study of Screening for Prostate Cancer evaluated 162,000 men and showed a 20% reduction in cancer-specific mortality for screened men. 6 However, the screening benefit was restricted to men age 55 to 69 years.
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
For advocates of screening, the recommended age at which to obtain the initial PSA, along with suggested frequency of screening, widely vary. The American Urological Association and American Cancer Society (ACS) published recommendations that are based on multidisciplinary expert opinion and that emphasize the importance of discussing and offering screening to men with at least 10 years of estimated life expectancy. 7, 8 For men who elect to undergo screening, a baseline PSA level between age 40 to 50 years is recommended, depending on individual risk factors. 7, 8 When to discontinue annual screening presents a particular challenge. The maximum ages included in the randomized trials were 69 years 5 and 74 years, 6 thereby limiting the amount of available data to guide evidence-based decisions for older men. Data from a longitudinal cohort study suggests that men age 75 years or older with a PSA less than 3.0 ng/mL have a negligible risk of prostate cancer-specific death, thereby suggesting screening can safely be excluded in these men. 9 On the basis of expert opinion recommendation from the American Urological Association, PSA screening in men with less than a 10-year life expectancy, either because of age or comorbidity, is discouraged. 7 Similarly, the ACS recommends that asymptomatic men who have at least a 10-year life expectancy have an opportunity to make an informed decision. 8 In distinct contrast, the United States Preventive Services Task Force recently suggested an age-based cutoff to stop routine screening at age 75 years. 10 To additionally inform this important and common clinical situation, our primary objective was to estimate the proportion of contemporary civilian US men age 70 years and older who underwent PSA-based prostate cancer screening. Our secondary objective was to estimate predictors of screening and determine whether estimated life expectancy was associated with screening patterns.
METHODS

Data Source and Participants
Data were extracted from the National Health Interview Survey (NHIS), a public access database containing responses from the noninstitutionalized civilian population of the United States. The NHIS is a cross-sectional household survey administered through a series of face-to-face interviews conducted by employees of the US Census Bureau. The cancer screening survey is administered every 5 years as a supplement to the standard NHIS, and response data from 2000 and 2005 were extracted. Because interviewees are randomly selected from the population, the chance of an individual being included in both survey years (2000 and 2005) is exceedingly unlikely.
Men age 70 years and older were included and separated into 5-year groups (70 to 74 years, 75 to 79 years, 80 to 84 years, and Ն 85 years of age). Of the 3,305 men age 70 years and older participating in the NHIS survey (adult cancer module), 340 had a history of prostate cancer, 288 had missing values on status of PSA test use (eg, refused to answer, answer was not ascertained, did not know), and 54 had missing values on date of most recent PSA test. After excluding these participants, 2,623 men were included in the analysis, representing approximately 8.1 million men age 70 years and older in the United States in 2000 and 8.0 million men of that age in the United States in 2005. By using the same criteria, men age 40 to 69 years old (n ϭ 11,984) were also included in the analyses as a comparative control.
Data Measurement
In both the 2000 and 2005 surveys, male respondents older than age 40 years who had received a PSA test were asked the main reason for their most recent PSA test. Response categories included part of a routine exam, because of a problem, or some other reason. In the 2000 survey, men could also answer follow-up test for an earlier exam or family history. Our primary outcome, PSA screening test, was defined as receipt of a PSA test as part of a routine exam within the year before the survey.
Our primary factor of interest was life expectancy. We measured 5-year life expectancy by using a validated mortality index based on NHIS data that included age, sex, smoking status, body mass index (BMI), comorbidities, recent hospitalizations, self-perceived health, and functional status measures. The index categorized 5-year mortality risk as high (Ն 48% risk of mortality), intermediate (16% to 47%), or low (Յ 15%). 11 We also prespecified and evaluated other factors thought to be associated with PSA screening among older men. These factors were race, ethnicity, place of birth, educational attainment, marital status, health insurance (eg, Medicare, private insurance), visits with a generalist or specialist within the previous year, a family history of any cancer, a family history of prostate cancer, utilization of colorectal cancer screening, vitamin use, alcohol use, and activity level.
Statistical Analyses
After accounting for sampling weight and study design (strata and primary sampling units 11a ), PSA screening rate was estimated according to age group, survey year, category of life expectancy, and other potential predictors. We also estimated the total number of men receiving a PSA test according to age group and category of life expectancy after taking account of sampling weight. Logistic regression for survey data was used to compare PSA screening rate by survey year. Because there was no substantial difference in the pattern of screening rate by age group between the two surveys, we pooled data from year 2000 and 2005 surveys to increase efficiency. Sensitivity analysis was done for each survey year, and the results were similar. Logistic regressions were also used to examine predictors of PSA testing among men age 70 years or older. Univariate analyses were done first, followed by age-adjusted analyses, as age was the strongest predictor for PSA screening. All variables found to be significant in age-adjusted analyses were included in a multivariate analysis. Because age is a component of the estimated life expectancy, we adjusted for age to interpret the association between life expectancy and PSA screening on the basis of other component parts of life expectancy. Multicollinearity can cause predictors to compete and make the selection of important variables arbitrary in a stepwise selection procedure. Therefore, we checked and found no important collinearity among variables that were significant in age-adjusted analysis. Then, we used backward stepwise logistic regression procedure to find independent predictors. To understand the overall influence of life expectancy as well as the influences of individual components of life expectancy, we present two final models: one model included estimated life expectancy, and the other model included component parts of the life expectancy calculation. Stata statistical software version 11.0 (Stata, College Station, TX) was used to complete all the analyses, and a P value less than .05 was considered statistically significant.
RESULTS
PSA-Based Prostate Cancer Screening Rates
The overall PSA screening rate in men age 40 years and older was 23.7% in 2000 and was 26.0% in 2005 in the United States. However, it varied dramatically by age (P Ͻ .001; Fig 1) . The PSA screening rate was lowest in the 40-to 44-year-old age group, and the rate increased with age until a plateau occurred at ages 65 to 79 years (44.6% in ages 65 to 69 years, 45.5% in ages 70 to 74 years, and 44.2% in ages 75 to 79 years). Then, the rate decreased to 24.6% in the Ն 85-year-old age group. The pattern of screening rate by age group was similar between 2000 and 2005 (P ϭ .32), so we combined data from 2000 and 2005 to increase precision of estimates in the subsequent analyses. An estimated 1.5 million men age 80 years or older reported a screening PSA test within the prior year (Table 1) .
Among men age 70 years and older, screening rates were associated with estimated 5-year life expectancy: 47.3% of men with high life expectancies (Յ 15% probability of 5-year mortality), 39.2% with intermediate life expectancies (16% to 47%), and 30.7% with low life expectancies (Ն 48%; P Ͻ .001; Table 1 ). The estimated total number of men with Ն 48% probability of 5-year mortality who received PSA testing was 777,000. No material differences in screening rates were observed between men with low and intermediate life expectancies in each age group of 75 to 79 years, 80 to 84 years, or Ն 85 years.
After analysis was adjusted for age, estimated life expectancy remained associated with PSA screening, although the strength of association was attenuated. This was expected, because age is a component of predicting life expectancy (P ϭ .034; Table 2 ). Higher rates of PSA screening in men age 70 years or older were also associated with the following: younger age, higher estimated life expectancy, non-Hispanic white ethnicity, place of birth, socioeconomic status, frequency of physician visits, insurance status, lifestyle choices, and higher functional status measures (Table 2) .
In multivariate analysis that adjusted for several predictors of PSA screening, estimated life expectancy maintained its significant association (Table 3 ; model 1). However, only two factors in the calculation of life expectancy were associated with lower PSA screening rates: older age and help in daily activities (Table 3; 
DISCUSSION
Estimated life expectancy and absolute age have both been proposed as criteria for considering prostate cancer screening, although virtually all consensus guidelines favor an estimated life expectancy of at least 10 years.
7,12-14 By using a contemporary, population-based, US survey, our study showed that PSA-based prostate cancer screening patterns are discordant with recommended guidelines and that PSA screening is utilized at an unnecessarily high rate with modest consideration of PSA Screening (%) Abbreviations: PSA, prostate-specific antigen; NA, not applicable.
‫ء‬
Defined as Յ 15% probability of 5-year mortality. †Defined as 16% to 47% probability of 5-year mortality. ‡Defined as Ն 48% probability of 5-year mortality. competing medical risks and estimated longevity. Our findings suggest that approximately three quarters of a million men with an estimated life expectancy of approximately 5 years received PSA screening in the year prior. These men are unlikely to reap a meaningful benefit.
There are multiple consequences of inordinate PSA screening. By ordering a PSA test, the physician has presumably chosen to recommend a prostate biopsy if the result is considered abnormally elevated. A prostate biopsy is an invasive procedure that can be associated with pain, stress while awaiting the results, 15 and a 4% risk of serious infection or bleeding requiring hospital readmission. 16 Second, of men who undergo biopsy, a significant minority (approximately 25% to 40%) will be diagnosed with prostate cancer, which leads to anxiety, 17 decision about a management strategy, and exposure to potential treatment-related morbidity. 18 Last, the PSA test, clinic visits, staging, treatment, and post-treatment follow-up cumulatively add individual and societal health care expenses. 19 When considering whether to obtain a PSA, a patient should be informed of these potential risks, intended benefits, and associated implications.
Age was a strong predictor of PSA screening but not in the expected pattern, as men who were age 70 to 79 years underwent PSA screening at nearly twice the rate of men age 50 to 54 years. A recent randomized trial demonstrated a modest overall cancer-specific survival advantage for screened patients, a finding limited to men younger than age 70 years. 6 On the basis of our observations and of those in the randomized screening trial, the men most likely to benefit from PSA screening are paradoxically being screened at markedly lower rates than men highly unlikely to benefit.
Accurately evaluating life expectancy is critical when considering management options in elderly patients considering prostate cancer screening. Age and comorbidities, as quantified by Charlson index scores or similar indices, are the strongest predictors of non-cancer-specific mortality, 20 and, intuitively, patients with a larger number or severity of comorbidities are less likely to benefit from screening. Modestly accurate tools are available to predict life expectancy in patients with localized prostate cancer (concordance index, 0.70 to 0.84) but are clinically underutilized. [21] [22] [23] [24] [25] Physicians are notoriously poor at estimating life expectancy, 26 which may explain the elevated screening rates of elderly men who are unlikely to survive another 5 years. Patients and physicians may also be uncomfortable discussing estimated life expectancy, although life expectancy is important when considering treatment decisions and clinical outcomes. 27 This reluctance may contribute to a tendency to excessively screen elderly patients who have limited life expectancies.
Physician confidence in the benefits of cancer screening may contribute to overutilization of PSA-based screening, as the majority of male physicians older than age 50 years self-reported having had a PSA test for the purposes of screening. 28 Elevated screening rates of elderly men with limited life expectancies may also reflect defensive medicine in response to previous litigation stemming from the decision not to offer prostate cancer screening.
29-31
The discordance between PSA screening recommendations and practice patterns has also been identified within the Veterans Affairs (VA) medical system. In 2003, 56% of men Ն 70 years old received a PSA test, and 36% of men Ն 85 years old received a PSA test. 32 Similar to our findings, marital status, socioeconomic status, and ethnicity were associated with screening rates. Although overall health status in the VA study, as measured by the Charlson score, was independently associated with screening, it did not markedly alter screening rates within each age category.
The Behavioral Risk Factor Surveillance System, a population-based telephone survey in the United States sampling 30,000 men older than 50 years in 2001, found that 57% reported a PSA test within the past year. 33 Approximately two thirds (69%) of men age 70 to 79 years and greater than half (56%) of men age 80 years or older reported a PSA test within the past year. Similar to our findings, increasing age was directly associated with rates of PSA screening. Our estimates from 2005 are substantially lower compared with those of the Behavioral Risk Factor Surveillance System survey in 2001.
33 These differences may stem from an encouraging modification of practice patterns or may reflect different methodologies. However, because we did not observe any temporal changes in screening patterns between 2000 and 2005 within the NHIS, we strongly favor different methodologies as the likely explanation. 
